Norvir Exclusivity Is Safe; NIH Says "March-In" Test Is Availability, Not Price
This article was originally published in The Pink Sheet Daily
Executive Summary
Abbott has met the requirements of the Bayh/Dole Act, NIH declares. "March-in" rights are not the right way to address drug pricing, agency says: that is up to Congress.
You may also be interested in...
After Xtandi, Will Government Ever Seek March-In Rights Over Drug Pricing?
Market availability of Xtandi, not its cost, is the issue, NIH says in denying petition for government to invoke march-in rights to patents on the prostate cancer drug. But Biden administration makes two other same-day moves that could leave march-in advocates with some hope.
End Of The 'March-In' Pricing Petitions?
KEI vows to continue battle over Bayh-Doyle restrictions after US Commerce Department suggests it may issue regulations to exclude pricing as a basis for requiring companies to license their patents.
NIH Resists “March In” On Norvir Patents Based On Pricing Concerns
NIH will not invoke its “march-in” authority under the Bayh-Dole Act to allow broader access to Norvir patents, Director Francis Collins says in response to a petition.